BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37954786)

  • 1. Cryptogenic Stroke Caused by a Newly Diagnosed Patent Foramen Ovale in a Healthy Young Adult.
    Ukponmwan EU; Banga S; Kim AG; Qintar M; Abela G
    Cureus; 2023 Oct; 15(10):e46895. PubMed ID: 37954786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
    Wiktor DM; Carroll JD
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Paradoxical Embolism (RoPE)-Estimated Attributable Fraction Correlates With the Benefit of Patent Foramen Ovale Closure: An Analysis of 3 Trials.
    Kent DM; Saver JL; Ruthazer R; Furlan AJ; Reisman M; Carroll JD; Smalling RW; Jüni P; Mattle HP; Meier B; Thaler DE
    Stroke; 2020 Oct; 51(10):3119-3123. PubMed ID: 32921262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermediate and long-term results of transcatheter closure of patent foramen ovale using the amplatzer patent foramen ovale occluder: one case of pulmonary embolism irrespective of patent foramen ovale closure.
    Yoon JH; Kim JS; Lee DH; Shim EJ; Lee SY; Min KS; Cho DJ; Lee HR
    Korean Circ J; 2011 Jul; 41(7):356-62. PubMed ID: 21860636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements.
    Elzanaty AM; Patel N; Sabbagh E; Eltahawy EA
    Curr Med Res Opin; 2021 Mar; 37(3):377-384. PubMed ID: 33460329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
    Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
    Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study.
    Kasner SE; Thomassen L; Søndergaard L; Rhodes JF; Larsen CC; Jacobson J
    Int J Stroke; 2017 Dec; 12(9):998-1004. PubMed ID: 29090661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.
    Turc G; Calvet D; Guérin P; Sroussi M; Chatellier G; Mas JL;
    J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29910193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptogenic Strokes and Patent Foramen Ovales: What's the Right Treatment?
    Dalen JE; Alpert JS
    Am J Med; 2016 Nov; 129(11):1159-1162. PubMed ID: 27566504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
    Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
    Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances and Ongoing Controversies in Patent Foramen Ovale Closure and Cryptogenic Stroke.
    Gonzalez JB; Testai FD
    Neurol Clin; 2021 Feb; 39(1):51-69. PubMed ID: 33223089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
    Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial.
    Lee PH; Song JK; Kim JS; Heo R; Lee S; Kim DH; Song JM; Kang DH; Kwon SU; Kang DW; Lee D; Kwon HS; Yun SC; Sun BJ; Park JH; Lee JH; Jeong HS; Song HJ; Kim J; Park SJ
    J Am Coll Cardiol; 2018 May; 71(20):2335-2342. PubMed ID: 29544871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptogenic Stroke and Patent Foramen Ovale.
    Mojadidi MK; Zaman MO; Elgendy IY; Mahmoud AN; Patel NK; Agarwal N; Tobis JM; Meier B
    J Am Coll Cardiol; 2018 Mar; 71(9):1035-1043. PubMed ID: 29495983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.
    Saver JL; Carroll JD; Thaler DE; Smalling RW; MacDonald LA; Marks DS; Tirschwell DL;
    N Engl J Med; 2017 Sep; 377(11):1022-1032. PubMed ID: 28902590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with medical treatment in patients with cryptogenic embolism (PC-Trial): rationale and design.
    Khattab AA; Windecker S; Jüni P; Hildick-Smith D; Dudek D; Andersen HR; Ibrahim R; Schuler G; Walton AS; Wahl A; Mattle HP; Meier B
    Trials; 2011 Feb; 12():56. PubMed ID: 21356042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patent foramen ovale and cryptogenic stroke: the hole story.
    Furlan AJ; Jauss M
    Stroke; 2013 Sep; 44(9):2676-8. PubMed ID: 23908069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patent Foramen Ovale, the Role of Antiplatelet Therapy Alone or Anticoagulant Therapy Alone Versus Device Closure for Cryptogenic Stroke: A Review of the Literature and Current Recommendations.
    Nagarajarao HS; Ojha CP; Kedar A; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2020; 18(2):135-150. PubMed ID: 32013839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late thrombosis of Gore Cardioform septal occluder device in a patient with history of patent foramen ovale closure.
    Khalil MH; Haider M; Mehta S
    Radiol Case Rep; 2024 Apr; 19(4):1386-1390. PubMed ID: 38268740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.